Axovant races to PhIII dementia study as nelotanserin clears an early hurdle, but questions linger
Axovant says that its drug nelotanserin has cleared an early hurdle in a Phase II study for Lewy body dementia, triggering a decision to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
